MT_KevinvTest

Kevin Sullivan, MBA

Chief Executive Officer

Mr. Sullivan has over 15 years of experience working with early stage biotechnology companies and has raised over $37M in private equity and non-dilutive government funding in biotechnology. Most recently he was Chief Executive Officer at DeNovaMed Inc., a biotechnology company focused on development of Gram-negative and Gram-positive antibiotics. Previously, he was Chief Operating Officer at Viron Therapeutics, a biopharmaceutical company developing a novel immunotherapy and recipient of the Prix Galien Award for Biotechnology. At Viron, he and his team completed development of the Company’s lead program through Phase 2 clinical development with Series A and B financing from a syndicate of international venture capital including two pharma-venture participants. He is an active mentor and volunteer advisor for several start-up biotechnology companies. Mr. Sullivan received a BSc in Immunology from Dalhousie University, a Graduate Certificate in Biotechnology from McGill University and an MBA from Western University.

MT-Stephens

Kimberly Stephens

Chief Financial Officer

Ms. Stephens brings over 16 years of financial management experience and senior financial positions with private and public companies. Most recently, she served as CFO of Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF) from 2011-2016, where she managed the raising of more than $40 million through equity financings and government grants. Prior to joining Immunovaccine Inc., Ms. Stephens served as director of finance for the Canadian subsidiary of Germanischer Lloyd.  She has also been the director of finance for SolutionInc, and started her career as an audit manager in the assurance and advisory group at PwC.  Ms. Stephens holds a bachelor of commerce degree from Mount Allison University and is a chartered professional accountant (CPA).

Jamie_Image_Bio_MTv3_Test

Jamie Doran MSc, DABT, ERT

Director of Drug Development

Ms. Doran has over 14 years experience as a regulatory toxicologist. She has broad experience in the development, monitoring and evaluation of nonclinical studies designed to test the safety, metabolism and distribution of new products (pharmaceuticals and chemicals) entering international markets. Ms. Doran has managed and prepared pre-IND, IND and CTA submissions to the US FDA and Health Canada as well as successfully managed preclinical and clinical programs in various indications.